SEQSTER, a healthcare technology company focused on connecting, collecting, and organizing patient health data, has announced an expanded collaboration with Praxis Precision Medicines, Inc. The partnership builds on earlier success and is aimed at speeding up clinical trials, improving data collection, and strengthening real world evidence generation across Praxis’ central nervous system research programs. By continuing to work together, the two companies seek to streamline how clinical studies are executed while improving the quality and continuity of patient data used throughout development.

Health Technology Insights: Hyperfine Announces Regulatory Approval of the Swoop System in India

The expanded partnership follows strong results from Praxis’ Essential3 Program, which focuses on essential tremor. SEQSTER’s platform is now also supporting the broader ENERGY program, Praxis’ clinical development initiative advancing vormatrigine as a potential treatment for epilepsy. Through this work, SEQSTER enables access to patient consented electronic health records from across the United States healthcare system, helping Praxis identify eligible participants, support enrollment, and maintain ongoing data collection across studies.

Health Technology Insights: Rona Launches First Bi-valent PCSK9-LPA siRNA for Heart Risk

Megan Sniecinski, Chief Operating Officer at Praxis Precision Medicines, shared that SEQSTER has played a critical role in helping the company run trials more efficiently. She explained that the platform has supported faster enrollment while also capturing long term real world data that is essential for advancing Praxis’ development programs. She added that the collaboration reflects a shared focus on bringing meaningful therapies to patients with CNS conditions more quickly and effectively.

SEQSTER’s technology is currently being used to support Praxis’ EMPOWER observational study, which is part of the larger ENERGY program. ENERGY includes both observational and interventional studies, such as EMPOWER and POWER, and has engaged more than five thousand patients living with epilepsy. The ability to securely integrate longitudinal patient data allows Praxis to better understand disease progression and treatment impact over time, strengthening both clinical and real world insights.

Ardy Arianpour, Chief Executive Officer of SEQSTER, noted that Praxis exemplifies the type of innovative sponsor SEQSTER aims to support. He emphasized that Praxis recognizes the value of real world data and is open to rethinking traditional clinical trial models. Arianpour stated that SEQSTER is proud to have built trust with Praxis across multiple studies and looks forward to continuing the partnership as Praxis works to deliver new treatment options for patients with CNS disorders.

The announcement aligns with the SCOPE Summit 2026, taking place February 2 through 5 in Orlando, Florida, where both SEQSTER and Praxis Precision Medicines will be present. The expanded partnership highlights a growing industry focus on integrating real world data and modern digital tools to improve the speed, efficiency, and impact of clinical research.

Health Technology Insights: Wealth Enhancement to Acquire Wealth Advocates with $476 Million AUM

To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com